To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Inclusion Criteria

• •Male and female participants aged 18 years or older (Japan, aged 20 years or older).
• •Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
• •Prior systemic treatment with at least 1 anti-CD20 mAb (either as monotherapy or in combination as chemoimmunotherapy)
• •Documented disease that has relapsed or progressed or was refractory after the most recent prior systemic therapy. Note: Participants must not be refractory to anti-CD20 mAb
• •Radiographically (CT, MRI) measurable lymphadenopathy per the Lugano criteria for response assessment (Cheson et al 2014).
• •ECOG PS of 0 to 2
• •Adequate organ functions including hematopoiesis, liver, and kidney
• •Willingness to avoid pregnancy or fathering children
• •History of other malignancy within 2 years of study entry.
• •Any condition that would, in the investigator's judgment, interfere with full participation in the study.